Venus Remedies enters into Partnership with West Pharmaceutical Services,Inc. to Launch Cloti-Xa™ in India with NovaGuard' SA Pro Safety System

Venus Remedies Limited is a research and development driven global pharmaceutical company and among the leading injectable manufacturers in the world, recently announced its partnership with West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, for its new introduction in the fast-growing low molecular weight heparin market with brand Cloti-Xa™, which has adopted NovaGuard@ SA Pro safety system, a single-use accessory for prefilled ISO standard 1mL long staked-needle syringes.

Cloti-Xa™ which contains enoxaparin sodium is being introduced with added advantage of NovaGuardo SA Pro safety system which is a revolutionary product that helps and protects healthcare workers and patients from accidental needlestick injuries. This innovative product has been commented to deliver a compelling total cost of ownership in that it prevents preactivation, offers a lower syringe snap-in force and a lower activation force for end-user comfort, and mitigates the practice of recapping which helps to provide tamper evidence to customers.

Mr. Saransh Chaudhary, Chief Executive Officer, Venus Medicine Research Centre said, "We are delighted to enter into a partnership with West to produce Cloti-Xa™ PFS with the innovative NovaGuard@ SA Pro safety system in India - Cloti-Xa™ is expected to provide patients and healthcare providers with an additional advantage of safety fiom accidental needle stick injuries, which could lead to the spread ofinfections like HIV, HepatitiS B and C. So far, no other enoxaparin formulation in India seems to offer this additional benefit apart from the innovator brand. Enoxaparin use has increased significantly in ICUs after it has been found useflrl in reducing hospitalization and mortality in COVID-l9 patients. I am positive that it is going to be a high yielding addition to our portfolio, and we intend to add more such innovative products iny'o our product line."

The NovaGuard@ SA Pro safety system in Cloti-Xa™:

- Has been designed to prevent pre-activation during handling;
- Includes tamper-resistant functionality;
- Provides transparency for drug inspection and labeling;
- Is easy to use for healthcare practitioners as it does not require any change in drug administration technique;
- Helps in reducing needlestick injuries and improve OSHA compliance

Speaking on the partnership, Mr. Alagu Subrananiam, Managing Director, West India said, "we are excited to extend our partnership with Venus Remedies on this new product launch. By delivering unique and innovative packaging products and services, we at West are committed to improving patients' health. This partnership helps us bring the benefits of our innovative NovaGuard@ SA Pro safety system to the India market and we will continue to extend the range ofour innovative products to local customers and patients worldwide."

The NovaGuard@ SA Pro lml- safety system has FDA 510k clearance in the U.S. and meets the European 2010/32/EU directive for the prevention of sharps injuries. Designed for both cut and circular syringe flange, the NovaGuard@ SA Pro safety system has design features that lock when used and has minimal impact upon syringe filling lines.

The NovaGuard@ SA Pro safety system has also won the India Packaging Awards for Excellence in Enhanced User Experience and Excellence in Packaging Design - Shapes and Structures during the UBM InnoPack Pharma Conference's India Packaging Awards ceremony.

Shares of VENUS REMEDIES LTD. was last trading in BSE at Rs.276 as compared to the previous close of Rs. 287.5. The total number of shares traded during the day was 13521 in over 656 trades.

The stock hit an intraday high of Rs. 288 and intraday low of 274. The net turnover during the day was Rs. 3726610.

Source : Equity Bulls

Keywords